Park Medi World IPO Date, Price, GMP, Reviews, Details 2025
The Park Medi World IPO 2025 is set to open for subscription from December 10 to 12, with a price band fixed at ₹154-₹162 per share. This IPO offers investors an opportunity to evaluate the company’s financial performance, GMP trends, and lot size details before making an informed investment decision. A practical rule: consider applying only if subscription builds strongly and GMP sustains above 20%.
The Park hospital IPO is drawing high interest because healthcare continues to be one of India’s strongest long-term structural sectors. Park Medi World Ltd, operating under the Park Hospitals brand, has expanded rapidly across North India with multi-speciality hospitals focused on middle-income households.
As investors evaluate the upcoming Park Medi World IPO Date, Park Medi World IPO Price and market sentiment reflected through the Park Medi World IPO GMP, the issue becomes important for both long-term investors and short-term traders looking for listing gains.
Park Medi World IPO Dates and Timeline
Event | Date |
Park Medi World IPO Date (Open) | December 10, 2025 |
Park Medi World IPO Date (Close) | December 12, 2025 |
Basis of Allotment | December 15, 2025 |
Initiation of Refunds | December 16, 2025 |
Shares Credit to Demat Account | December 16, 2025 |
Park Medi World IPO Listing Date | December 17, 2025 |
Park Medi World Ltd Overview
Park Medi World Ltd was incorporated in 2011 and today operates a network of multi-speciality hospitals under the Park Hospitals branding. The chain focuses on affordability, volume-led healthcare and essential specialities such as orthopaedics, cardiac sciences, neurology, general surgery, critical care and mother-and-child care. The company manages and operates hospitals with a combined planned capacity of more than 3,000 beds and a robust mix of doctors, nurses and technical staff.
The business has a strong regional cluster across Haryana, Delhi, Punjab and Rajasthan, a structure that allows medical staff sharing, better utilisation of diagnostic infrastructure and strong brand recall in its focus markets. Its positioning in Tier 2 and Tier 3 cities also supports a steady patient flow and favourable occupancy whenever economic and seasonal conditions are stable.
Park Medi World IPO Details
Particulars | Details |
IPO Name | Park Medi World Ltd |
IPO Type | Book-Built Issue (Mainboard) |
Total Issue Size | Approx. ₹920 crore |
Fresh Issue | Around ₹770 crore |
Offer for Sale (OFS) | About ₹150 crore |
Face Value | ₹2 per share |
Park Medi World IPO Price Band | ₹154 – ₹162 per share |
Listing on | NSE and BSE |
Estimated Post-Issue Market Cap | ₹6,900 – ₹7,000 crore (approx.) |
Promoter Holding (Post-Issue) | Slightly reduced but majority-controlled |
Use of Proceeds | Expansion, debt repayment, medical equipment procurement, and selective acquisitions |
Park Medi World IPO Lot Size
- Retail investors can apply for lots of 92 shares.
- Retail minimum investment: approx ₹14,904 at the upper price band.
- Retail maximum (13 lots): approx ₹1.93 lakh.
- Small HNI minimum: 14 lots.
- Big HNI minimum: 68 lots.
Use of IPO Proceeds
The company intends to channel the net proceeds of the fresh issue into two major areas: capital expenditure (including a new hospital under the Park Medicity subsidiary and medical equipment procurement) and repayment or prepayment of borrowings. A part of the funds is also earmarked for inorganic growth opportunities, including possible hospital acquisitions or operational management agreements.
The remainder will go toward general corporate purposes. This structure suggests that a meaningful share of the Park hospital IPO will directly strengthen the balance sheet and support the next phase of expansion.
Financial Performance Summary
Park Medi World has demonstrated steady revenue growth over FY23-FY25. Revenue for FY25 stands at roughly ₹1,426 crore, growing over FY24 despite muted occupancy in some quarters. EBITDA has expanded to the ₹370 crore range, yielding margins in the mid-20s. PAT for FY25 is around ₹213 crore, marking a strong rebound from FY24 performance. Return ratios remain attractive, with RoE trending near 20%.
Operational metrics show a planned bed capacity exceeding 3,000 with more than 800 ICU beds. However, occupancy has moderated from the mid-70% range in FY23 to the low 60% range in FY25. This remains one of the key variables to watch in coming years. ARPOB (Average Revenue Per Occupied Bed) remains lower than many large listed peers, reflecting the company’s mass-market pricing philosophy but also limiting aggressive revenue growth per patient.
Valuation Overview
Based on restated FY25 earnings per share of approximately ₹5.55, the upper price band of ₹162 implies a P/E multiple of about 29-30 times earnings. This places Park Medi World at a discount compared to many listed hospitals that trade at higher multiples, especially premium-focused chains.
The discount appears justified by lower ARPOB, regional concentration and occupancy volatility, but on the whole, valuation appears fair for a mid-sized, fast-scaling chain. Long-term investors may view this as an opportunity to enter a growth-stage regional healthcare company at a valuation below that of national chains.
Park Medi World IPO GMP Trend
The Park Medi World IPO GMP (Grey Market Premium) has hovered around ₹14 per share during the issue window. This translates to an estimated 8-9% premium over the upper end of the price band. GMP has softened slightly compared to the early trend as subscription has remained moderate.
While GMP is unofficial, unregulated and can fluctuate significantly, many traders treat it as a short-term sentiment indicator. For readers tracking short-term listing gain opportunities, the Park hospital IPO GMP will matter more on the last day when institutional subscription becomes clearer.
Subscription Status
Subscription trends indicate moderate but steady participation. Retail and HNI categories have shown near-full to modest oversubscription in early days, while QIB participation typically builds strongly on Day 3. The final subscription numbers will play a major role in determining whether the listing is likely to be strong or subdued.
Healthcare IPOs historically attract strong institutional demand, but given the valuation and occupancy-related questions, investors should observe how QIB demand evolves before taking a call.
Key Strengths
Park Medi World has a deep regional footprint in North India, especially Haryana, where it is one of the largest hospital chains by bed count. Its multi-speciality portfolio includes cardiology, oncology, orthopaedics, critical care and surgery, which tend to be strong-margin segments. The company has demonstrated consistent ability to grow through acquisitions and operational management of underperforming hospitals.
The company has continued to enhance its profitability with decent EBITDA margins and high RoE. Credibility is improved by NABH and NABL accreditation in major hospitals. The middle-range pricing structure provides a high number of patients in middle-income households, the essence of its value model.
Key Risks
Despite its strengths, Park Medi World also carries important risk factors. Geographic concentration is a major concern, with a significant portion of revenues coming from Haryana. Occupancy volatility is another challenge, as utilisation has come down over the last two years.
ARPOB remains lower than larger peers, limiting pricing flexibility. Doctor attrition in certain verticals and regulatory compliance requirements in the healthcare sector create operational uncertainties. Debt reduction through the IPO will help, but continuous expansion requires disciplined capital allocation.
Should You Apply for Park Medi World IPO?
Park Medi World offers a combination of reasonable valuation, strong regional dominance, improving profitability and a clear expansion roadmap. For short-term listing gains, investors may consider applying only if final QIB subscription builds substantially and the Park Medi World IPO GMP stays above the 20% threshold.
For long-term investors, the chain’s growth potential, bed addition strategy and improving margins offer interesting prospects, though risks around occupancy and geographic concentration must be accounted for. This article provides an educational decision framework and is not a recommendation.
How to Check IPO Allotment Status?
Once the Park Medi IPO closes and allotment is processed, investors can check status in the following way:
- Visit the IPO registrar’s official allotment page
- Enter PAN, application number or DP ID
- Submit to view your allotment status
- If allotted, shares appear in the demat account before listing
- If not allotted, the blocked amount is automatically released under ASBA
The allotment for Park Medi IPO is expected on December 15, with listing expected on December 17.
Conclusion
The Park Medi World IPO 2025 presents a promising opportunity for investors interested in the rapidly expanding healthcare and diagnostics sector. With a strong business model, consistent financial growth, and clear utilization of proceeds toward expansion and debt reduction, the Park hospital IPO reflects solid fundamentals.
Investors however are well advised to study the Park Medi IPO GMP trends, Park Medi World IPO date, Park Medi World IPO price, valuation as well as the general market conditions before subscribing. As usual, long-term financial objectives and risk tolerance are prudent in matching any IPO investment.
Disclaimer
The article is purely educational and is not an indication to purchase/ sell or apply to Park Medi World IPO. Before one makes a decision on investing, they should do some independent research, read official documents and consult a registered financial adviser.
FAQ'S
What is the Park Medi World IPO date? and price band?
The IPO opens on 10 December 2025 and closes on 12 December 2025.
What is the Park Medi World IPO price?
The Park Medi World IPO price band is ₹154-₹162 per share.
What is the lot size for Park Medi World IPO?
The lot size is 92 shares, requiring a minimum investment of about ₹14,904 at the upper price band.
What is the current Park Medi World IPO GMP?
The GMP has been around ₹14 per share during the issue, indicating an expected listing premium of roughly 8-9%.
How is Park Medi World performing financially?
The company reported revenue of approximately ₹1,426 crore and PAT of around ₹213 crore in FY25 with EBITDA margins in the mid-20s.
How should an investor decide whether to apply?
Short-term traders often consider applying only if both final subscription and GMP are strong. A GMP above 20% and strong QIB bidding are commonly used signals. This is not a recommendation.
